Astellas Pharma : Initiatives for Gene Therapy(2,933KB)
March 15, 2022 at 01:00 am EDT
Share
INITIATIVES FOR GENE THERAPY
R&D Meeting - March 9, 2022
Astellas Proprietary Information
CAUTIONARY STATEMENT
2
REGARDING FORWARD-LOOKING INFORMATION
In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas Pharma. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively,
the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.
Astellas Proprietary Information
AGENDA
3
Introduction
Kenji Yasukawa, Ph.D.
President and Chief Executive Officer
Building Leadership in Gene Therapy
Mathew Pletcher, Ph.D.
Division Head of Gene Therapy Research & Technical Operations
Update on Clinical Programs in Gene Therapy
Bernhardt (Bernie) Zeiher, M.D. Chief Medical Officer
Astellas Proprietary Information
INTRODUCTION
Kenji Yasukawa, Ph.D.
President and Chief Executive Officer
Astellas Proprietary Information
WHY WE WORK ON GENE THERAPY
5
Gene therapy has the potential to be transformative for patients, their families and society
by addressing the root cause of disease, which provides a variety of VALUEs
FOCUS AREA APPROACH
Biology
Modality/
Technology
Pathophysiology
Versatile
characterized
technology
Disease
Disease with
high unmet medical needs
Primary Focus Genetic Regulation has been selected based on;
Scientific validity
Feasibility
Identified lead program and potential follow-on programs
ASTELLAS' COMMITMENT TO GENE THERAPY
2010's
2020
2021
2022
Exploratory research
Acquisition of
Astellas Gene Therapies
New manufacturing
on gene therapy
Audentes
as Gene Therapy
facility in Sanford,
Center of Excellence
North Carolina1
1. Scheduled to be operational by mid-2022
Astellas Proprietary Information
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Astellas Pharma Inc. published this content on 15 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 March 2022 04:59:00 UTC.
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders.
Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).